Log In
BCIQ
Print this Print this
 

PDC41

  Manage Alerts
Collapse Summary General Information
Company Theratechnologies Inc.
DescriptionTopical formulation of prostaglandin F2a receptor antagonist
Molecular Target Prostaglandin F (FP) receptor (PTGFR)
Mechanism of ActionProstaglandin F (FP) receptor antagonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase I
Standard IndicationDysmenorrhea
Indication DetailsTreat primary dysmenorrhea
Regulatory Designation
PartnerPDC Biotech GmbH

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today